References
- Wakelee H, Belani CP. Optimizing first-line treatment options for patients with advanced NSCLC. Oncologist 2005;10:1-10.
- Pujol J, Barlesi F, Daurès J. Should chemotherapy combinations for advanced non-small cell lung cancer be platinum-based? A meta-analysis of phase III randomized trials. Lung Cancer 2006;51:335-45.
- Shepherd FA, Pereira J, Ciuleanu T, Tan EH, Hirsh V, Thongprasert S, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005;353:123-32.
- Bezjak A, Tu D, Seymour L, Clark G, Trajkovic A, Zukin M, et al. Symptom improvement in lung cancer patients treated with erlotinib: Quality of life analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR.21. J Clin Oncol 2006;24:3831-7.
- Amin MB, Greene FL, Edge SB, Compton CC, Gershenwald JE, Brookland RK, et al. The eighth edition AJCC cancer staging manual: Continuing to build a bridge from a population-based to a more “personalized” approach to cancer staging. CA A Cancer J Clin 2017;67:93-9.
- Maeno T, Satoh H, Ishikawa H, Yamashita, YT, Naito T, Fujiwara M, et al. Patterns of pancreatic metastasis from lung cancer. Anticancer Res 1998;18:2881-4.
- Brahmer JR, Rodríguez-Abreu D, Robinson AG, Hui R, Csőszi T, Fülöp A. Health-related quality-of-life results for pembrolizumab versus chemotherapy in advanced, PD-L1-positive NSCLC (KEYNOTE-024): A multicentre, international, randomised, open-label phase 3 trial. Lancet Oncol 2017;18:1600-9.
- Wang F, Fu S, Shao Q, Zhou Y, Zhang X, Zhang X, et al. High EGFR copy number predicts benefits from tyrosine kinase inhibitor treatment for non-small cell lung cancer patients with wild-type EGFR. J Transl Med 2013;11:90.
- Ramalingam S, Sandler AB. Salvage therapy for advanced non-small cell lung cancer: Factors influencing treatment selection. Oncologist 2006;11:655-65.
- Clark GM, Zborowski DM, Santabárbara P, Ding K, Whitehead M, Seymour L, et al. Smoking history and epidermal growth factor receptor expression as predictors of survival benefit from erlotinib for patients with non-small-cell lung cancer in the National Cancer Institute of Canada Clinical Trials Group Study BR. 21. Clin Lung Cancer 2006;7:389-94.
- Reck M, van Zandwijk N, Gridelli C, Baliko Z, Rischin D, Allan S, et al. Erlotinib in advanced non-small cell lung cancer: Efficacy and safety findings of the global phase IV tarceva lung cancer survival treatment study. J Thorac Oncol 2010;5:1616-22.
- Ciuleanu T, Stelmakh L, Cicenas S, Miliauskas S, Grigorescu AC, Hillenbach C, et al. Efficacy and safety of erlotinib versus chemotherapy in second-line treatment of patients with advanced, non-small-cell lung cancer with poor prognosis (TITAN): A randomised multicentre, open-label, phase 3 study. Lancet Oncol 2012;13:300-8.
- Groen H, Arrieta OG, Riska H, Horwood K, Mali P, Reck M. The global TRUST study of erlotinib in advanced non-small-cell lung cancer (NSCLC). J Clin Oncol 2008;26 15 Suppl:19000.
- Silvestri G, Pritchard R, Welch HG. Preferences for chemotherapy in patients with advanced non-small cell lung cancer: Descriptive study based on scripted interviews. BMJ 1998;317:771-5.
- Lynch TJ Jr., Kim ES, Eaby B, Garey J, West DP, Lacouture ME. Epidermal growth factor receptor inhibitor-associated cutaneous toxicities: An evolving paradigm in clinical management. Oncologist 2007;12:610-21.
- Petrelli F, Borgonovo K, Cabiddu M, Lonati V, Barni S. Relationship between skin rash and outcome in non-small-cell lung cancer patients treated with anti-EGFR tyrosine kinase inhibitors: A literature-based meta-analysis of 24 trials. Lung Cancer 2012;78:8-15.